CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing oncolytic immunotherapies for patients with bladder cancer. They aim to provide innovative therapies to improve the quality of life for urologic cancer patients worldwide.
Industries
Nr. of Employees
medium (51-250)
Patents
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US-11497781-B2
View Details
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US-11497781-B2
View DetailsProducts
Intravesical oncolytic adenoviral immunotherapy (adenovirus-based, GM‑CSF transgene)
A selectively replicating adenoviral therapeutic designed to preferentially replicate in tumor cells with dysfunctional retinoblastoma (Rb) pathways, causing oncolysis and releasing tumor antigens and GM‑CSF to stimulate systemic anti-tumor immunity. Developed for intravesical administration in bladder cancer and evaluated as monotherapy and in combination with checkpoint inhibitors.
Intravesical oncolytic adenoviral immunotherapy (adenovirus-based, GM‑CSF transgene)
A selectively replicating adenoviral therapeutic designed to preferentially replicate in tumor cells with dysfunctional retinoblastoma (Rb) pathways, causing oncolysis and releasing tumor antigens and GM‑CSF to stimulate systemic anti-tumor immunity. Developed for intravesical administration in bladder cancer and evaluated as monotherapy and in combination with checkpoint inhibitors.
Services
Sponsorship and operational management of multi-center and global clinical trials in bladder cancer, including endpoint definition, site coordination, safety monitoring and data reporting.
Structuring and executing regional license and commercialization agreements with milestone and royalty terms, including co-development and territory-specific arrangements.
Sponsorship and operational management of multi-center and global clinical trials in bladder cancer, including endpoint definition, site coordination, safety monitoring and data reporting.
Structuring and executing regional license and commercialization agreements with milestone and royalty terms, including co-development and territory-specific arrangements.
Expertise Areas
- Oncolytic immunotherapy development
- Clinical trial management (Phase 1–3) for oncology
- Combination immunotherapy development with checkpoint inhibitors
- Translational research and biomarker integration
Key Technologies
- Oncolytic adenoviral vectors
- Intravesical local delivery
- GM-CSF transgene expression
- Cancer-selective promoter (E2F-type) regulation
News & Updates
Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C. 58.3% of patients showed durable complete responses by K-M at 24 months. 97.3% of all treated patients remained free from progression to MIBC at 24 months.
Interim results from the global Phase 2 study (CORE1) of CG0070 in combination with pembrolizumab show promising early efficacy and tolerability, with 88% of evaluable patients achieving complete response at 3 months, maintained through 12 months.
Cold Genesys completed a Series B financing co-led by Ally Bridge Group and WI Harper Group with $10 million to advance CG0070 in pivotal studies for bladder cancer.
Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C. 58.3% of patients showed durable complete responses by K-M at 24 months. 97.3% of all treated patients remained free from progression to MIBC at 24 months.
Interim results from the global Phase 2 study (CORE1) of CG0070 in combination with pembrolizumab show promising early efficacy and tolerability, with 88% of evaluable patients achieving complete response at 3 months, maintained through 12 months.
Cold Genesys completed a Series B financing co-led by Ally Bridge Group and WI Harper Group with $10 million to advance CG0070 in pivotal studies for bladder cancer.